These are the stocks posting the largest moves before the bell.Market Insiderread more
The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
U.S. stock index futures were higher Tuesday morning after results from major companies topped expectations.US Marketsread more
In advance of Amazon's earnings report on Thursday, Craig Johnson says the stock chart is pointing to big gains. Mark Tepper also likes the stock.Trading Nationread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
Lockheed Martin turned in second-quarter earnings on Tuesday that were above what Wall Street anticipated.Marketsread more
The Trump administration on Tuesday will propose a rule to tighten food stamp restrictions that would cut about 3.1 million people from the program, U.S. Department of...Politicsread more
conviction@ (Recasts to reflect details from court hearing, adds defense lawyer's comments, other details)
NEW YORK, June 28 (Reuters) - A lawyer for former pharmaceutical executive Martin Shkreli on Friday urged a federal appeals court to overturn Shkreli's criminal conviction for defrauding investors in hedge funds he founded.
The lawyer, Mark Baker, argued that the jury that convicted Shkreli was given incorrect instructions about securities fraud. Baker faced a barrage of skeptical questions from a three-judge panel during a brief proceeding in the 2nd U.S. Circuit Court of Appeals in Manhattan.
Shkreli, 36, gained notoriety as the "Pharma Bro" after founding Turing Pharmaceuticals, buying the anti-parasitic drug Daraprim and raising its price by 5,000 percent, to $750 per pill in 2015.
He was charged with securities fraud and conspiracy in December 2015, convicted by a federal jury in Brooklyn in August 2017 and sentenced to seven years in prison last year. He was also ordered to forfeit more than $7 million.
His criminal case stemmed from two hedge funds and a drug company he had founded years before Turing. The jury found that he defrauded investors in the funds, MSMB Capital and MSMB Healthcare, by sending them fake account statements and concealing huge losses, and schemed to prop up the stock price of the drug company, Retrophin Inc.
The jury acquitted him of related wire fraud conspiracy charges, for which it received slightly different instructions. Baker argued on Friday that the split verdict showed the instructions had made the difference.
"The split verdict in this case speaks volumes as to the care the jury took," he said.
Circuit Judge Joseph Bianco, however, said the jury instructions appeared necessary after Shkreli's lawyer at trial suggested that Shkreli could not be guilty because he eventually paid his investors back.
Circuit Judge Debra Ann Livingston pressed Baker on that point: "A belief that ultimately no one will be harmed is not a defense to a securities fraud case, correct?"
Baker conceded that it was not.
Assistant U.S. Attorney Alixandra Smith, arguing for the prosecution, said the different instructions for securities fraud and wire fraud reflected a difference in the laws on those crimes.
In a brief rebuttal, Baker said that even if Shkreli's conviction stands, the fact that he eventually paid back investors should "wipe out" his obligation to forfeit cash.
The Brooklyn-born Shkreli, the son of Albanian immigrants, is scheduled to be released from prison in October 2023 if he fails to get his conviction tossed out. (Reporting by Brendan Pierson in New York Editing by Jonathan Oatis and Matthew Lewis)